Pharmacological profile of T-0632, a novel potent and selective CCK(A) receptor antagonist, in vitro

European Journal of Pharmacology

Volumn 304, Issue 1-3, 1996, Pages 147-154

  Taniguchi, Hiroyuki ^a   Yazaki, Naoko ^a   Endo, Toshio ^a   Nagasaki, Masaaki ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

amylase release; CCK(A) receptor; gallbladder; gallbladder contraction; pancreas; T 0632

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMYLASE; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; IODINE 125; KETANSERIN; LOXIGLUMIDE; MEPYRAMINE; METHYLSCOPOLAMINE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NEUROTRANSMITTER RECEPTOR; NEW DRUG; PRAZOSIN; RADIOLIGAND; RAUWOLSCINE; SEROTONIN; SPIPERONE; T 0632; UNCLASSIFIED DRUG;

AMYLASE RELEASE; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BRAIN; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENCY; DRUG SELECTIVITY; GALLBLADDER; GUINEA PIG; MALE; NONHUMAN; PANCREAS ACINUS; PRIORITY JOURNAL; RABBIT; RAT; RECEPTOR BINDING; SMOOTH MUSCLE CONTRACTILITY;

EID: 0030598633     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00091-X     Document Type: Article

References (36)

1. Akiyama, T. and M. Otsuki, 1994. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini, Pancreas 9, 324.
2. Beglinger, C., S. Dill, B. Meyer, B. Werth and G. Adler, 1989. Treatment of biliary colic with loxiglumide, Lancet 8655, 167.
3. Bhat, S.T., V.D. Talkad, D.A. Polio and J.D. Gardner, 1994, Characterization of a persistent inhibitory action of L-364,718 on cholecystokinin-stimulated enzyme secretion in pancreatic acini. Pancreas 9. 101.
4. Bond, R.A., A.G. Ornstein and D.E. Clarke, 1989. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation, J. Pharmacol. Exp. Ther. 249, 401.
5. Bradford, M.M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248.
6. Cann, P.A., L.C. Rovati, H. Smart, R.C. Spiller and P.J. Whorwell. 1993. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome: a pilot multicenter clinical study. Gastroenterology 104, A486.
7. Cerezo, J.G., R. Codoceo, P.F. Calle, F. Molina, J.M. Tenias and J.J. Vazquez, 1991. Basal and postprandial cholecystokinin values in chronic pancreatitis with and without abdominal pain, Digestion 48, 134.
8. Ceska, M., K. Birath and B. Brown, 1969, A new and rapid method for the clinical determination of α-amylase activities in human serum and urine. Optimal conditions. Clin. Chim. Acta 26, 437.
9. Chang, R.S.L. and V.J. Lotti, 1986, Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist, Proc. Natl. Acad. Sci. USA 83, 4923.
10. Chang, R.S.L., P.K.S. Siegl, B.V. Clineschmidt, N.B. Mantlo, P.K. Chakravarty, W.J. Greenlee, A.A. Patchett and V.J. Lotti, 1992. In vitro pharmacology of L-158,809. a new highly potent and selective angiotensin II receptor antagonist, J. Pharmacol. Exp. Ther. 262, 133.
11. Chua, A., M. Bekkering, L.C. Rovati and P.W.N. Keeling, 1993, Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in non-ulcer dyspepsia, Gastroenterology 104, A491.
12. Crawley, J.N. and R.L. Corwin, 1994, Biological actions of cholecystokinin, Peptides 15, 731.
13. 8 as radioligand, J. Neurosci. 4, 1021.
14. A receptors, Eur. J. Pharmacol. 232, 13.
15. Innis, R.B. and S.H. Snyder, 1980, Distinct cholecystokinin receptors in brain and pancreas, Proc. Natl. Acad. Sci. USA 77, 6917.
16. Ito, H., H. Sogabe, T. Nakarai, Y. Sato, M. Tomoi, M. Kadowaki, M. Matsuo, K. Tokoro and K. Yoshida, 1994, Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. J. Pharmacol. Exp. Ther. 268, 571.
17. Lee, Y.M., M. Beinborn, E.W. McBride, M. Lu, L.F. Kolakowski, Jr. and A.S. Kopin, 1993, The human brain cholecystokinin-B/gastrin receptor. J. Biol. Chem. 268, 8164.
18. Liddle, R.A., 1994, Cholecystokinin, in: Gut Peptide, eds. J.H. Walsh and G.J. Dockray (Raven Press, New York) p. 175.
19. A-receptor antagonist derived from the cholecystokinin C-terminal dipeptide, Biomed. Chem. Lett. 3, 1511.
20. Modlin, I.M., A.J. Bilchik and K.A. Zucker, 1989. Cholecystokinin augmentation of 'surgical' pancreatitis: benefits of receptor blockade, Arch. Surg. 124, 574.
21. 2-receptor antagonist, IT-066, with the receptor in the atria of guinea pig, Jpn. J. Pharmacol. 57, 13.
22. Noda, M., Y. Shibouta, Y. Inada, M. Ojima, T. Wada, T. Sanada, K. Kubo, Y. Kohara, T. Naka and K. Nishikawa, 1993, Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem. Pharmacol. 46, 311.
23. Okabayashi, Y., M. Otsuki, T. Nakamura, M. Fujii, S. Tani, T. Fujisawa, M. Koide, H. Hasegawa and S. Baba, 1990, Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas, Pancreas 5, 291.
24. Otsuki, M., M. Fujii, T. Nakamura, Y. Okabayashi, S. Tani, T. Fujisawa, M. Koide and S. Baba, 1989, Loxiglumide: a new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas, Dig. Dis. Sci. 34, 857.
25. 2 receptor blockade by SR 48968 and MEN 10,627 in the guinea-pig isolated gallbladder and colon, Eur. J. Pharmacol. 271, 111.
26. 2-receptor antagonist, Arch. Int. Pharmanodyn. 266, 4.
27. Perdikis, G., P. Wilson, R.A. Hinder, E.J. Redmond, G.J. Wetscher, S. Saeki and T.E. Adrian, 1994, Gastroesophageal reflux disease is associated with enteric hormone abnormalities, Am. J. Surg. 167, 186.
28. Pisegna, J.R., A.D. Weerth, K. Huppi and S.A. Wank, 1992, Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization, Biochem. Biophys. Res. Commun. 189, 296.
29. Sankaran, H., I.D. Goldfine, A. Bailey, V. Licko and J.A. Williams, 1982, Relationship of cholecystokinin receptor binding to regulation of biological functions in pancreatic acini. Am. J. Physiol. 242, G250.
30. Setnikar, I., M. Bani, R. Cereda, R. Chisté, F. Makovec, M.A. Pacini, L. Revel, L.C. Rovati and L.A. Rovati, 1987, Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneim. Forsch./Drug Res. 37, 703.
31. Taniguchi, H., M. Nagasaki and H. Tamaki, 1995, Effects of cholecystokinin (CCK)-JMV-180 on the CCK receptors of rabbit pancreatic acini and gallbladder smooth muscle, Jpn. J. Pharmacol. 67, 219.
32. Verspohl, E.J., H.P.T. Ammon, J.A. Williams and I.D. Goidfine, 1986, Evidence that cholecystokinin interacts with specific receptors and regulates insulin release in isolated rat islets of Langerhans, Diabetes 35, 38.
33. Wank, S.A., R, Harkins, R.T. Jensen, H. Shapira, A.D. Weerth and T. Slattery, 1992, Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas, Proc. Natl. Acad. Sci. USA 89, 3125.
34. Wienen, W., A.B.M. Mauz, J.C.A. Meel and M. Entzeroth, 1992, Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies, Mol. Pharmacol. 41, 1081.
35. Williams, J.A., M. Korc and R.L. Dormer, 1978, Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini, Am. J. Physiol. 235, E517.
36. Yamazaki, Y., M. Akahane, M. Kobayashi, M. Kitazawa, Y. Kurashina and K. Iizuka, 1993, Pharmacological profile of KSG-504, a new cholecystokinin-A-receptor antagonist, Jpn. J. Pharmacol. 63, 219.